GOVX Company Profile and Key Details

GeoVax Labs, Inc. trades at a P/E ratio of -0.24, slightly below the S&P 500 average, with a price-to-sales ratio of 2.84 and a price-to-book ratio of 10.27 reflecting a rich premium to book value. The P/FCF stands at -0.13, also above market averages. Compared to sector medians, GeoVax Labs, Inc. P/S is trading at a discount to the sector, and the P/B is far lower than peers, underscoring the brand and earnings power premium investors assign to the stock.

GeoVax Labs, Inc. generated EPS of -$47.34 over the past year. Five-year average earnings growth is 78.99%. Wall Street analysts project EPS growth of 51.06% annually over the next five years. The latest quarter delivered EPS of -$2.62. The next quarter is forecast at -$5.67. Next year's EPS is expected at $18.28. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 7 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $1.00. The high target offers 307.24% upside. The low target suggests -54.75% downside. The mean target is $7.25. This offers 228.05% upside. GeoVax Labs, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 14, 2026, missed forecasts by -25.19%. The prior quarter beat by -51.35%. Over the last six quarters, Apple has recorded several small beats. These include -62.03% in March 27, 2025.

GeoVax Labs, Inc. (NASDAQ:GOVX) closed at $2.21 USD, gaining $0.98 (79.67%) from the previous close of $1.23. The stock is currently mid-range between its 52-week high and low $0.96 and $34.75. With a market capitalization of about $2.12 million, GeoVax Labs, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~3.35). Key stats such as the average daily volume over the past year has been around 3.63 million shares, trading with heavier-than-usual volume. Headquartered in Smyrna, GA, GeoVax Labs, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David Alan Dodd, the company employs approximately 17 people and listed since September 25, 2020. GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform.

GOVX has shown weak momentum, losing -21.85% over the past week and -79.8% over the past quarter, though year-to-date performance is down -34.74%. Short-term trend indicators are bullishly aligned (SMA20 -26.59%, SMA50 -53.4%, SMA200 -88.57%). The stock’s 14-day RSI is 28.5 (weak momentum), while the ATR of 0.32 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -96.6% below its high and over 26.98% above its low. Average 10-day trading volume of 29.95 million shares is significantly above the 3-month average of 3.81 million, indicating heightened recent market interest.

GeoVax Labs, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.79. This means the shares are trading above this model’s fair value.

GeoVax Labs, Inc. has 25.36 million shares outstanding. The public float is 19.93 million shares, elevated short interest at 14.77% of float. This equals 3.73 million shares. The short ratio is 1.37 days. Institutional investors hold 13.55% of the float. Insiders own 6.07%. EMORY UNIVERSITY holds 231.07 million shares, Tsolinas Peter M has 431.73 thousand shares and ROBINSON HARRIET L has 223.88 thousand shares.

Our AI price prediction model suggests that GeoVax Labs, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -20.36%, with price expected at $1.76 by June 01, 2026, within a range of $1.50 to $2.00 3-Month Outlook: Projected fall of -98.64%, reaching $0.03 by August 13, 2026, with a range of $0.00 to $0.92. 1-Year Outlook: Projected loss of -95.48%, with price at $0.10 by May 18, 2027, within a range of $0.00 to $2.91.

GeoVax Labs, Inc. (NASDAQ:GOVX) shares are down -34.74% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows GeoVax Labs, Inc. trading at a premium to the broader market with a P/E of -0.24. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $14.17, suggesting 541.18% upside. Our AI forecast model points to short-term weakness (-20.36% over two weeks), a medium-term fall (-98.64% over three months), and a longer-term loss (-95.48% over one year), with expected trading ranges indicating moderate volatility.